Archive | Health Professionals

The Role of BRAF Mutations in Melanoma

My name is Adil Daud. I’m a medical oncologist. I work at the University of California, San Francisco, where I direct melanoma research and the melanoma program.

Read the full story

Posted in Melanoma News, Health Professionals, Video Reports

Melanoma: Progression After Immunotherapy

Jeffrey S. Weber, MD, PhD: Let’s transition to the elephant in the room. We’ve heard great things about single-agent PD-1 [programmed cell death protein 1] blockade, ipilimumab-nivolumab, BRAF/MEK—multiple combinations, all frontline therapy.

Read the full story

Posted in Melanoma News, Health Professionals, Video Reports

Combination Therapy in Mutated Melanoma

The big impact of MEK inhibitors has been 2-fold. One is that it delays resistance, which you know, you have this additional blockade for cells that have somehow managed to live without BRAF.

Read the full story

Posted in Melanoma News, Health Professionals, Video Reports

Novel Agents for the Treatment of Melanoma

Jeffrey S. Weber, MD, PhD: There’s a whole raft of phase III trials that will come to mature—SD-101, CMP-001, the MASTERKEY-265—and then there’s the NKTR-nivolumab trial.

Read the full story

Posted in Melanoma News, Health Professionals, Video Reports